UBS maintains IFF stock Neutral rating, $83 target

UBS maintained a Neutral rating on International Flavors & Fragrances (IFF) with an $83 price target, noting the company's reduced net debt-to-EBITDA ratio following the Pharma divestment shifts focus to growth. While IFF's Taste and Scent segments show strength, UBS anticipates underperformance relative to peers due to limitations in the Food Ingredients division, warranting a valuation discount; however, other analysts have issued more favorable ratings. IFF recently completed the sale of its nitrocellulose business to reduce debt and focus on core areas, reporting 3% organic growth in Q1, with BofA Securities, Tigress Financial Partners, Oppenheimer, and Barclays issuing Buy/Outperform/Overweight ratings and raised price targets based on the company's strategic investments, debt reduction, and reliable financial guidance.

Analysis

International Flavors & Fragrances (IFF) has materially improved its leverage profile, with its net debt-to-EBITDA ratio projected to decrease from approximately 4x in 2024 to 2.8x in 2025 following the completion of its Pharma divestment. This strategic deleveraging shifts the central investment question from balance sheet risk to the company's growth prospects, as highlighted by UBS analyst Joshua Spector, who maintains a Neutral rating and an $83 price target. Spector suggests IFF may underperform peers due to its current portfolio composition, particularly citing the Food Ingredients division (now a separate segment from Taste) as a constraint on both margins and growth, thus warranting a valuation discount. This cautious stance contrasts with more optimistic views from other analysts: BofA Securities raised its price target to $92 (Buy), Tigress Financial Partners initiated with a Buy, Oppenheimer maintained an Outperform ($89 target), and Barclays upgraded to Overweight ($84 target). These firms point to IFF's successful divestitures, including the recent sale of its nitrocellulose business, strong Q1 organic growth of 3%, effective debt reduction, and reliable 2025 financial guidance. While IFF's Taste and Scent segments have demonstrated stronger recent growth compared to competitors, its Health/Bio segment has underperformed. InvestingPro data indicates IFF's Financial Health score is "FAIR" at 2.3 out of 5, reflecting a mixed fundamental picture despite strategic refocusing on core flavors, fragrances, and biosciences.

Key Decisions for Investors

• Investors should carefully evaluate the divergent analyst opinions, weighing UBS's concerns about IFF's organic growth potential against the more bullish outlooks from other firms citing successful strategic repositioning and debt reduction.
• Monitor the performance of IFF's distinct segments, particularly the recently separated Food Ingredients division and the Health/Bio segment, as their respective growth trajectories will be critical to achieving overall corporate targets and validating the current strategic direction.
• Consider IFF's improved financial flexibility due to divestitures and debt paydown, but remain attentive to whether the streamlined portfolio can deliver peer-leading growth and margin expansion to potentially rerate the stock.